share_log

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax Pharmaceuticals | 10-K/A: Annual report (Amendment)

Virpax制药 | 10-K/A：年度报表(修正版)
美股SEC公告 ·  10/11 05:10

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a net loss of $21.7 million for the year ended December 31, 2022, compared to a net loss of $12.1 million for the previous year. The company's accumulated deficit reached approximately $44.4 million. Despite the losses, Virpax has cash reserves of around $19.0 million. The company is involved in litigation with potential damages up to $35.0 million, but has accrued $2 million for this purpose. Virpax's primary source of capital has been through equity securities issuance, including a successful initial public offering (IPO) and an underwritten public offering in 2021. The company's financial statements have been prepared under the assumption that it will continue as a going concern, although there is substantial doubt due to ongoing losses and litigation uncertainties. Virpax is focused on developing non-opioid pain management treatments and CNS disorder treatments. The company relies on third-party contract manufacturing organizations (CMOs) for production and has entered into various research and licensing agreements to advance its product candidates.
Virpax制药公司，一家处于临床前阶段的药品公司，截至2022年12月31日止年度净亏损达2170万美元，相比前一年的净亏损1210万美元。该公司的累积赤字达到约4440万美元。尽管亏损，Virpax拥有约1900万美元的现金储备。该公司正与可能达到3500万美元的诉讼案件进行诉讼，但已为此目的提取了200万美元。Virpax的主要资本来源是通过股权证券发行，包括一次成功的首次公开发行（IPO）和2021年的承销公开发行。该公司的财务报表是在假设其将继续作为持续经营实体的前提下编制的，尽管由于持续亏损和诉讼不确定性而存在重大疑虑。Virpax专注于研发非阿片类疼痛管理和中枢神经系统疾病治疗。该公司依赖第三方合同制造组织（CMOs）进行生产，并已签署各种研究和许可协议以推进其产品候选品。
Virpax制药公司，一家处于临床前阶段的药品公司，截至2022年12月31日止年度净亏损达2170万美元，相比前一年的净亏损1210万美元。该公司的累积赤字达到约4440万美元。尽管亏损，Virpax拥有约1900万美元的现金储备。该公司正与可能达到3500万美元的诉讼案件进行诉讼，但已为此目的提取了200万美元。Virpax的主要资本来源是通过股权证券发行，包括一次成功的首次公开发行（IPO）和2021年的承销公开发行。该公司的财务报表是在假设其将继续作为持续经营实体的前提下编制的，尽管由于持续亏损和诉讼不确定性而存在重大疑虑。Virpax专注于研发非阿片类疼痛管理和中枢神经系统疾病治疗。该公司依赖第三方合同制造组织（CMOs）进行生产，并已签署各种研究和许可协议以推进其产品候选品。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间